Early safety check for new lung drug combo
NCT ID NCT07229716
Summary
This early-stage study aims to understand how a new drug called HRS-9813 interacts with two existing pulmonary fibrosis medications (pirfenidone and nintedanib) in healthy volunteers. Researchers will measure how the drugs affect each other's levels in the body and monitor for side effects. The study involves 20 healthy adults and focuses on safety and drug interactions rather than treating the disease itself.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tangdu Hospital, Fourth Military Medical University
Xi’an, Shanxi, 710026, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.